BCR and cancer: The results obtained showed that CD276 was highly correlated with immunoregulatory interactions between lymphoid and a non-lymphoid cell and signaling medicated by the B-cell receptor BCR in many types of cancer, including BRCA, CHOL, GBM, LUSC, MESO, SARC, SKCM, THCA, UCEC and UCS.